The University of Alabama at Birmingham (UAB) continues to evolve as a worldwide leader in biomedicine, research and innovation.
Incysus Therapeutics, Inc., a Birmingham-based biopharmaceutical company, has now announced the initiation of a Phase 1 clinical study of a novel Drug Resistant Immunotherapy (DRI) technology for the treatment of patients with newly-diagnosed glioblastoma.
This trial is being conducted at UAB and is now active and open for enrollment.
Glioblastoma multiforme (GBM or glioblastoma) is a devastating and fast-growing brain tumor that typically results in death within the first 15 months after diagnosis. GBM is inherently resistant to conventional therapy and accounts for approximately 52% of all primary brain tumors.
A release from the company outlined Incysus’ innovative DRI approach, which seeks to combine conventional chemotherapies with a γδ T cell-based immunotherapy to modify the tumor microenvironment and drive the immune system. By using alkylating agents such as temozolomide, chemotherapy can activate immunity through the upregulation of the DNA damage response (DDR) pathway. A significant challenge is that such chemotherapies also kill the white blood cells needed to drive an immune response. Incysus’ technology “chemo-protects” immune cells to allow them to remain functional while DDR activation creates an immune signal that allows directed killing activity against cancer cells.
Incysus is the first company to use this type of therapy in patients, and the research marks a landmark moment for Incysus, the overall biotech industry in Birmingham and anti-cancer research across the globe.
Dr. L. Burt Nabors, MD, the co-head of neuro-oncology at UAB and the study’s principal investigator, stated, “The initiation of this clinical trial represents a significant milestone towards developing effective immune-based therapies for the treatment of GBM. We are pleased to work with … the team at Incysus to bring this innovative therapy to patients for the first time.”
Further information on the clinical trial is available here.
Incysus is a UAB spinoff company. Its success in the Magic City — and this kind of potentially revolutionary research spearheaded by UAB — is a prime example of why many legislative and industry leaders in the state, especially in the Birmingham area, are calling on Governor Kay Ivey to fund a world-class genomics facility at the university. They argue that the project could make Birmingham the “Silicon Valley of Biomedicine.”
Sean Ross is the editor of Yellowhammer News. You can follow him on Twitter @sean_yhn